A5012247336- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Glycosylation and Glycoproteins Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chemokine receptors and signaling
- Phytochemical compounds biological activities
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Immunotherapy and Immune Responses
- Hematological disorders and diagnostics
- Cancer therapeutics and mechanisms
- Cancer-related molecular mechanisms research
- Histiocytic Disorders and Treatments
- T-cell and B-cell Immunology
- HIV/AIDS drug development and treatment
- MicroRNA in disease regulation
- Ubiquitin and proteasome pathways
- Lymphoma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Viral-associated cancers and disorders
University Hospital Brno
2016-2025
Masaryk University
2014-2024
Massachusetts General Hospital
2021
University Hospital Ostrava
2016
University of Ostrava
2016
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible autologous stem-cell transplantation. Daratumumab has shown efficacy in standard-of-care regimens relapsed or refractory myeloma.
Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating cells (CTCs) until 2021, when this threshold decreased to 5%. We hypothesized that primary PCL not a separate clinical entity, but rather it represents ultra-high-risk multiple myeloma (MM) elevated CTC levels.We assessed levels of CTCs multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM establish cutoff for identifies...
Monoclonal gammopathy of undetermined significance is a pre-malignant precursor multiple myeloma with 1% risk progression per year. Although targeted analyses have shown the presence specific genetic abnormalities such as IGH translocations, RB1 deletion, 1q gain, hyperdiploidy or RAS gene mutations, little known about molecular mechanism malignant transformation. We performed whole exome sequencing together comparative genomic hybridization plus single nucleotide polymorphism array analysis...
Summary Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV) infusion multiple myeloma (MM). We describe the Phase II PLEIADES study of subcutaneous formulation daratumumab (DARA SC) in combination with standard‐of‐care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D‐VRd) transplant‐eligible newly diagnosed MM (NDMM); bortezomib/melphalan/prednisone (D‐VMP) transplant‐ineligible NDMM; and lenalidomide/dexamethasone (D‐Rd) relapsed/refractory MM....
Abstract Multiple myeloma is the second most common hematological malignancy characterized by focal lesions of malignant plasma cells in bone marrow. These contain subclones that directly influence survival patients. Bone marrow biopsies are single‐site and thus cannot all information about tumor. In contrast, liquid analyze circulating molecules secreted from sites Long noncoding RNA one class these molecules. We performed a two‐phase biomarker study investigating lncRNA expression profiles...
BackgroundIn the phase 3 ALCYONE study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) versus (VMP) significantly improved progression-free survival (PFS) and overall (OS) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. We present a subgroup analysis of by patient frailty status.Patients MethodsFrailty assessment was performed retrospectively using age, Charlson comorbidity index, baseline Eastern Cooperative Oncology Group performance status score....
Multiple myeloma (MM) represents the second most common hematological malignancy characterized by infiltration of bone marrow plasma cells that produce monoclonal immunoglobulin. While quality and length life MM patients have significantly increased, remains a hard-to-treat disease; almost all relapse. As is highly heterogenous, relapse at different times. It currently not possible to predict when will occur; numerous studies investigating dysregulation non-coding RNA molecules in cancer...
Extramedullary disease in multiple myeloma patients is an uncommon event occurring either at the time of diagnosis, or during progression/relapse. This manifestation frequently associated with poor outcome and resistance to treatment. We evaluated chromosomal alterations plasma cells extramedullary relapse, bone marrow (BM) sites, previous BM collection by interphase fluorescence situ hybridization.Thirty-one [25 (BMPCs), 18 tumor cells], which 12 had paired samples 14 BM, were investigated...
Long non-coding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that not translated into proteins. They involved in pathogenesis of many diseases including cancer and have a potential to serve as diagnostic prognostic markers. We aimed investigate lncRNA expression profiles bone marrow plasma cells (BMPCs) newly diagnosed multiple myeloma (MM) patients comparison normal BMPCs healthy donors (HD) three-phase biomarker study.Expression profile 83 was performed by RT2 PCR Array...
Abstract IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out multicenter retrospective study in patients with diagnosis of defined by >10% marrow involvement monoclonal plasma cells, presence an paraproteinemia any size, anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified FISH. A total 134 from 20 centers were included this analysis. The median age at...
Melflufen is a novel peptide–drug conjugate that rapidly delivers cytotoxic payload into tumor cells. It has emerged as potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe rationale and design OCEAN (NCT03151811), randomized, head-to-head, superiority, open-label, global, Phase III study evaluating efficacy safety melflufen + dexamethasone versus pomalidomide dexamethasone. Eligible patients with relapsed refractory have received 2–4...
Abstract Background We have performed a head to comparison of all-oral triplet combination ixazomib, lenalidomide and dexamethasone (IRD) versus (RD) in patients with relapsed refractory multiple myeloma (RRMM) the routine clinical practice. Methods A total 344 treated IRD ( N = 127) or RD 217) were selected for analysis from Czech Registry Monoclonal Gammopathies (RMG). Descriptive statistics used assess patient’s characteristics associated respective therapy. The primary endpoint was...
Background Multiple myeloma (MM) is a plasma cell malignancy frequently associated with impaired immune numbers and functions. In MM, several studies have previously shown that CD4 regulatory T (Treg) cells hamper effector functions enhance dysfunction. this study, we aimed to prove the presence of functionally suppressive Treg expressing CD8 phenotype (CD8 cells) in MM. To best our knowledge, has not been reported Methods We analyzed their transcription factor FoxP3 from 64 newly diagnosed...
Objective Subcutaneous (SC) application of bortezomib has been recently introduced as a new route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes bortezomib-based therapy patients treated using either intravenous (IV) or subcutaneous administration. Patients and methods During January 2012 through December 2013, we retrospective 446 with MM regimens (either once weekly – 63% twice 27%) both, first line setting, relapse, separate undergoing autologous stem...
Multiple myeloma (MM) is a highly heterogeneous disease of malignant plasma cells. Diagnosis and monitoring MM patients based on bone marrow biopsies detection abnormal immunoglobulin in serum and/or urine. However, have single-site bias; thus, new diagnostic tests early strategies are needed. Matrix-Assisted Laser Desorption/Ionization Time-of Flight Mass Spectrometry (MALDI-TOF MS) powerful method that found its applications clinical diagnostics. Artificial intelligence approaches, such as...
Abstract Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used this purpose; however, approach site‐limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that not site‐limited, but equally challenging. Methods While majority current data comes from short‐term studies, we present long‐term study on...
Characteristic recurrent copy number aberrations (CNAs) play a key role in multiple myeloma (MM) pathogenesis and have important prognostic significance for MM patients. Array-based comparative genomic hybridization (aCGH) provides powerful tool genome-wide classification of CNAs thus should be implemented into routine diagnostics. We demonstrate the possibility effective utilization oligonucleotide-based aCGH 91 Chromosomal associated with effect on prognosis were initially evaluated by...